COMBINED PDK AND MAPK/ERK PATHWAY INHIBITION IN NEOPLASIA

摘要

The current inventors have found a new method for treatment of malignant neoplasia. In particular the invention relates to the field of treating neoplasia in subject in need thereof and that involve (activated) MAPK/ERK pathway proteins, like BRAF melanomas and the like. Compositions for use in such treatment are provided which make use of pyruvate dehydrogenase kinase (PDK) inhibitors.